Fidaxomicin failures in recurrent Clostridium difficile infection: A problem of timing

Clinical Infectious Diseases

Volumn 55, Issue 4, 2012, Pages 613-614

  Orenstein, Robert ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CIPROFLOXACIN; FIDAXOMICIN; METRONIDAZOLE; VANCOMYCIN;

ADULT; CASE REPORT; CLOSTRIDIUM DIFFICILE INFECTION; COLITIS; DIARRHEA; FEMALE; HUMAN; HYPOKALEMIA; LETTER; PRIORITY JOURNAL; RECURRENT DISEASE; SACCHAROMYCES BOULARDII; TOOTH INFECTION;

ADULT; AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; FEMALE; HUMANS; MIDDLE AGED; RECURRENCE; TREATMENT FAILURE;

EID: 84864475752     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cis495     Document Type: Letter

References (4)

1. Kelly CP, LaMont JT. Clostridium difficile- more difficult than ever. N Engl J Med 2008; 359:1932-40.
2. Louie TJ, Miller MA, Mullane KM, et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl JMed 2011; 364:422-31.
3. Cornely OA, Crook DW, Espposito R, et al. Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomized controlled trial. Lancet Infect Dis 2012; 12:281-9.
4. Chang JY, Antonopoulos DA, Kalra A, et al. Decreased diversity of the fecal microbiome in recurrent Clostridium difficile-associated diarrhea. J Infect Dis 2008; 197:435-8.